A Phase 3 interventional study of Caffeine Citrate and Placebo in Apnea of Prematurity, sponsored by NICHD Neonatal Research Network. Terminated at 16 sites in United States. Open to participants aged 29 Weeks to 33 Weeks. Per ClinicalTrials.gov, last updated 2024-07-31.
Sponsored by NICHD Neonatal Research Network · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing caffeine citrate in Apnea — 5 open to participants now, 5 under way, none of them phase 3. caffeine citrate · Apnea.
Among the 18 studies testing caffeine citrate in Apnea, this one is the 3rd largest by enrollment, is one of 2 that started in 2019, is one of 6 in phase 3, and was the 11th registered.
282 studies on the registry are indexed under Apnea; 54 are open to participants now.
Browse Apnea studies →5 of the 18 studies testing caffeine citrate in Apnea are open now, in 3 countries. Recruiting first, the newest first:
University of Rochester · Sites in United States
Ages 0 days–27 wk
University of Alabama at Birmingham · Sites in Zambia
Ages 0 days–12 mo
Indiana University · Sites in United States
Ages 18+ · Women only
Semmelweis University · Sites in Hungary
University of Melbourne
Ages up to 32 wk
By country, each count listing its studies:
caffeine citrate: first FDA approval 1999 (CAFCIT), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 40 Apnea studies recruiting now, 9 (23%) set no upper age limit and 27 (68%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 29 Weeks to 33 Weeks · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 827 is above the median of 60 across 195 interventional studies indexed under Apnea.
Median enrollment 94 across the 18 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 18 have an industry lead sponsor. The 10 most frequent:
NICHD Neonatal Research Network is the lead sponsor of 63 studies on the registry; 5 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
NICHD Neonatal Research Network has 1 study filed under Apnea — fewer than ten, so there is no comparison to draw.
2 of the studies testing caffeine citrate in Apnea that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06518603University of Alabama at BirminghamCaffeine Citrate in Preterm Infants at Risk of Apnea in Zambia | 2027-05-31 |
| NCT07570121Indiana UniversityPharmacokinetics and Placental Transfer of Caffeine | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies testing caffeine citrate in Apnea, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the effect of continuing treatment with caffeine citrate in the hospital and at home in moderately preterm infants with resolved apnea of prematurity on days of hospitalization after randomization.
Study subjects will be patients in the NICU at one of the participating hospitals at a Neonatal Research Network site. Infants who meet the eligibility criteria will be randomized to either caffeine citrate at 10 mg/kg/dose or placebo (equal volume of all the excipients except for the active ingredient, caffeine citrate) to be given daily beginning within 72 hours of open label caffeine discontinuation. The infant may still require hospitalization for observation after discontinuation of open label caffeine or for other discharge issues such as temperature control or feeding tolerance.
Once deemed ready for discharge, infants will be continued at home on the same dose of caffeine citrate or placebo for the first 28 days after hospital discharge. On the day of discharge, the parent will be supplied with 28 numbered vials with oral caffeine citrate (intervention group) or placebo at an equivalent volume (placebo group).
The parents will be educated by the research nurse, discharge nurse, physician, or pharmacist on storage and administration of study medication. A member of the research team will contact the parents to obtain post-discharge information within 72 hours after discharge, once a week for the first 4 weeks, and biweekly during the weeks 5 to 8 after discharge.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Caffeine citrate at 10 mg/kg/dose (5 mg/kg caffeine base) daily, in hospital. Infants will continue at home on the same dose of caffeine citrate for the first 28 days after hospital discharge.
Drug: Caffeine Citrate
Placebo contains all of the excipients except for the active ingredient, caffeine citrate, (a volume equivalent to 10 mg/kg of caffeine citrate) and given daily. Infants will be continued at home on the same dose of placebo for the first 28 days after hospital discharge.
Drug: Placebo
The study intervention is caffeine citrate given once daily at 10 mg/kg/day. It is given orally, before hospital discharge and 28 days after discharge.
The study intervention is placebo given once daily at a volume equivalent to 10 mg/kg of caffeine citrate. It is given orally, before hospital discharge and 28 days after discharge.
Number of Days Between Randomization and Hospital Discharge
The number of days between randomization and hospital discharge. This outcome is censored at 48 weeks PMA and at time of transfer or death.
Time frame: Randomization through hospital discharge, censored at time of transfer, death, or 48 wks PMA
Number of Sick Visits Related to Apneic or Apparent Life-threatening Events Within First 4 Weeks Post-discharge
Number of sick visits related to apneic or apparent life-threatening events within first 4 weeks post-discharge MEASTYPE=SEC
Time frame: Discharge through 4 weeks post-discharge
The Number of Days to Physiologic Maturity After Randomization
The number of days to physiologic maturity after randomization. Physiologic maturity is defined: 1. Temperature: out of the incubator for at least 48 hours with normal body temperature; 2. Feeding: oral feeding at a volume of at least 140 ml/kg for 48 hours or growing on less than 140 ml/kg/day for at least 48 hours; 3. Respiratory: apnea-free for at least 5 consecutive days. This outcome is censored at 48 weeks PMA
Time frame: Randomization through hospital discharge, censored at time of transfer, death, or 48 wks PMA
The Number of Days to When Out of Incubator for 48 Hours: When Maintained Stable Temp for 48 Hrs
The number of days to when out of incubator for 48 hours: when maintained stable temp for 48 hrs. This outcome is censored at 48 weeks PMA
Time frame: Randomization through hospital discharge, censored at time of transfer, death, or 48 wks PMA
The Number of Days to Apnea/ Bradycardia Free for 5 Consecutive Days
The number of days to apnea/ bradycardia free for 5 consecutive days. This outcome is censored at 48 weeks PMA
Time frame: Randomization through hospital discharge, censored at time of transfer, death, or 48 wks PMA
The Number of Days to Oral Feeds >140 ml/kg/Day or Growing on Less Than 140 ml/kg/Day for at Least 48 Hours
The number of days oral feeds \>140 ml/kg/day or growing on less than 140 ml/kg/day for at least 48 hours. This outcome is censored at 48 weeks PMA
Time frame: Randomization through hospital discharge, censored at time of transfer, death, or 48 wks PMA
Post-menstrual Age at Discharge
The post-menstrual age of the infant at discharge censored at 48 weeks PMA and at time of transfer or death
Time frame: Randomization through hospital discharge, censored at time of transfer, death, or 48 wks PMA
Weight Gain From Randomization Until Status
Weight gain from randomization until status %(discharge up to 48 wks PMA, with censoring at time of transfer or death%).
Time frame: Randomization through hospital discharge, censored at time of transfer, death, or 48 wks PMA
The Number of Days After Randomization Until Status That Infant Had at Least Two Consecutive Heart Rates >200 Documented at Least 3 Hours Apart
The number of days after randomization until status that infant had at least two consecutive heart rates \>200 documented at least 3 hours apart
Time frame: Randomization through hospital discharge, censored at time of transfer, death, or 48 wks PMA
Treatment for High Blood Pressure
Treatment for high blood pressure initiated after randomization until status.
Time frame: Randomization through hospital discharge, censored at time of transfer, death, or 48 wks PMA
The Number of Episodes Between Randomization and Status That Infant Was Placed NPO for >= 24 Hours
The number of episodes between randomization and status that infant was placed NPO for \>= 24 hours
Time frame: Randomization through hospital discharge, censored at time of transfer, death, or 48 wks PMA
Use of Anti-reflux Medications
The use of anti-reflux medications started between randomization and status
Time frame: Randomization through hospital discharge, censored at time of transfer, death, or 48 wks PMA
Number of Days That Significant Apnea/Bradycardia
The number of days that significant apnea/bradycardia, as defined by documentation of infant receiving any of the following between randomization and status: open label caffeine, other methylxanthines, doxapram, CPAP or ventilatory support for apnea/bradycardia.
Time frame: Randomization through hospital discharge, censored at time of transfer, death, or 48 wks PMA
All-cause Mortality
All-cause mortality
Time frame: Randomization through hospital discharge, censored at time of transfer, death, or 48 wks PMA
Number of All-cause Readmissions Within First 4 Weeks Post-discharge
Number of all-cause readmissions within first 4 weeks post-discharge
Time frame: Discharge through 4 weeks post-discharge
Number of All-cause Readmissions Within Second 4 Weeks Post-discharge
Number of all-cause readmissions within second 4 weeks post-discharge
Time frame: 4 weeks through 8 weeks post-discharge
Number of All-cause Readmissions Within First 8 Weeks Post-discharge
Number of all-cause readmissions within first 8 weeks post-discharge
Time frame: Discharge through 8 weeks post-discharge
Number of All-cause Sick Visits, Urgent Care, Emergency Rooms, or Health Care Provider%'s Office, Within First 4 Weeks Post-discharge
Number of all-cause sick visits, urgent care, emergency rooms, or health care provider%'s office, within first 4 weeks post-discharge
Time frame: Discharge through 4 weeks post-discharge
Number of All-cause Sick Visits, Urgent Care, Emergency Rooms, or Health Care Provider%'s Office, Within Second 4 Weeks Post-discharge
Number of all-cause sick visits, urgent care, emergency rooms, or health care provider%'s office, within second 4 weeks post-discharge
Time frame: 4 weeks through 8 weeks post-discharge
Number of All-cause Sick Visits, Urgent Care, Emergency Rooms, or Health Care Provider%'s Office, Within First 8 Weeks Post-discharge
Number of all-cause sick visits, urgent care, emergency rooms, or health care provider%'s office, within first 8 weeks post-discharge
Time frame: Discharge through 8 weeks post-discharge
Number of Sick Visits Related to Apneic or Apparent Life-threatening Events Within Second 4 Weeks Post-discharge
Number of sick visits related to apneic or apparent life-threatening events within second 4 weeks post-discharge
Time frame: 4 weeks through 8 weeks post-discharge
Number of Sick Visits Related to Apneic or Apparent Life-threatening Events Within First 8 Weeks Post-discharge
Number of sick visits related to apneic or apparent life-threatening events within first 8 weeks post-discharge
Time frame: Discharge through 8 weeks post-discharge
Infants were recruited into the study based on eligibility and parental/guardian consent. Baseline characteristics of the mother were collected (with consent) for use in statistical analysis.
| Milestone | Caffeine Citrate | Placebo |
|---|---|---|
| Started | 416 | 411 |
| Completed in-hospital stay | 390 | 397 |
| Completed | 345 | 351 |
| Not completed | 71 | 60 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lost to follow-up | 31 | 35 |
| Withdrew: Still in hospital at 48 0/7 wks post-menstrual age (pma) | 1 | 1 |
| Withdrew: Transferred to another facility | 10 | 7 |
| Withdrew: Withdrawal by subject | 28 | 17 |
The number of days between randomization and hospital discharge. This outcome is censored at 48 weeks PMA and at time of transfer or death.
| days | Caffeine | Placebo |
|---|---|---|
| Number of Days Between Randomization and Hospital Discharge | 18 (10 to 30) | 16.5 (10 to 27) |
The number of days to physiologic maturity after randomization. Physiologic maturity is defined: 1. Temperature: out of the incubator for at least 48 hours with normal body temperature; 2. Feeding: oral feeding at a volume of at least 140 ml/kg for 48 hours or growing on less than 140 ml/kg/day for at least 48 hours; 3. Respiratory: apnea-free for at least 5 consecutive days. This outcome is censored at 48 weeks PMA
| days | Caffeine | Placebo |
|---|---|---|
| The Number of Days to Physiologic Maturity After Randomization | 13 (7 to 23) | 14 (8 to 23) |
The number of days to when out of incubator for 48 hours: when maintained stable temp for 48 hrs. This outcome is censored at 48 weeks PMA
| days | Caffeine | Placebo |
|---|---|---|
| The Number of Days to When Out of Incubator for 48 Hours: When Maintained Stable Temp for 48 Hrs | 5 (2 to 9) | 5 (1 to 9) |
The number of days to apnea/ bradycardia free for 5 consecutive days. This outcome is censored at 48 weeks PMA
| days | Caffeine | Placebo |
|---|---|---|
| The Number of Days to Apnea/ Bradycardia Free for 5 Consecutive Days | 8 (5 to 16) | 11 (5 to 18) |
The number of days oral feeds \>140 ml/kg/day or growing on less than 140 ml/kg/day for at least 48 hours. This outcome is censored at 48 weeks PMA
| days | Caffeine | Placebo |
|---|---|---|
| The Number of Days to Oral Feeds >140 ml/kg/Day or Growing on Less Than 140 ml/kg/Day for at Least 48 Hours | 14 (6 to 23) | 12 (5 to 22) |
The post-menstrual age of the infant at discharge censored at 48 weeks PMA and at time of transfer or death
| weeks | Caffeine | Placebo |
|---|---|---|
| Post-menstrual Age at Discharge | 37.7 (37.5 to 37.9) | 37.6 (37.4 to 37.8) |
Weight gain from randomization until status %(discharge up to 48 wks PMA, with censoring at time of transfer or death%).
| grams per day | Caffeine | Placebo |
|---|---|---|
| Weight Gain From Randomization Until Status | 28.9 (28.1 to 29.8) | 32.2 (30.9 to 33.4) |
The number of days after randomization until status that infant had at least two consecutive heart rates \>200 documented at least 3 hours apart
| days | Caffeine | Placebo |
|---|---|---|
| The Number of Days After Randomization Until Status That Infant Had at Least Two Consecutive Heart Rates >200 Documented at Least 3 Hours Apart | 0 (0 to 0) | 0 (0 to 0) |
Treatment for high blood pressure initiated after randomization until status.
| Participants | Caffeine | Placebo |
|---|---|---|
| No | 412 | 410 |
| Yes | 2 | 1 |
The number of episodes between randomization and status that infant was placed NPO for \>= 24 hours
| episodes | Caffeine | Placebo |
|---|---|---|
| The Number of Episodes Between Randomization and Status That Infant Was Placed NPO for >= 24 Hours | 0 (0 to 0) | 0 (0 to 0) |
The use of anti-reflux medications started between randomization and status
| Participants | Caffeine | Placebo |
|---|---|---|
| No | 384 | 387 |
| Yes | 30 | 24 |
The number of days that significant apnea/bradycardia, as defined by documentation of infant receiving any of the following between randomization and status: open label caffeine, other methylxanthines, doxapram, CPAP or ventilatory support for apnea/bradycardia.
| days | Caffeine | Placebo |
|---|---|---|
| Number of Days That Significant Apnea/Bradycardia | 0 (0 to 0) | 0 (0 to 0) |
All-cause mortality
| Participants | Caffeine | Placebo |
|---|---|---|
| No | 415 | 411 |
| Yes | 1 | 0 |
Number of all-cause readmissions within first 4 weeks post-discharge
| count of readmissions | Caffeine | Placebo |
|---|---|---|
| Number of All-cause Readmissions Within First 4 Weeks Post-discharge | 0 (0 to 0) | 0 (0 to 0) |
Number of all-cause readmissions within second 4 weeks post-discharge
| count of readmissions | Caffeine | Placebo |
|---|---|---|
| Number of All-cause Readmissions Within Second 4 Weeks Post-discharge | 0 (0 to 0) | 0 (0 to 0) |
Number of all-cause readmissions within first 8 weeks post-discharge
| count of readmissions | Caffeine | Placebo |
|---|---|---|
| Number of All-cause Readmissions Within First 8 Weeks Post-discharge | 0 (0 to 0) | 0 (0 to 0) |
Number of all-cause sick visits, urgent care, emergency rooms, or health care provider%'s office, within first 4 weeks post-discharge
| count of sick visits | Caffeine | Placebo |
|---|---|---|
| Number of All-cause Sick Visits, Urgent Care, Emergency Rooms, or Health Care Provider%'s Office, Within First 4 Weeks Post-discharge | 0 (0 to 0) | 0 (0 to 0) |
Number of all-cause sick visits, urgent care, emergency rooms, or health care provider%'s office, within second 4 weeks post-discharge
| count of sick visits | Caffeine | Placebo |
|---|---|---|
| Number of All-cause Sick Visits, Urgent Care, Emergency Rooms, or Health Care Provider%'s Office, Within Second 4 Weeks Post-discharge | 0 (0 to 0) | 0 (0 to 0) |
Number of all-cause sick visits, urgent care, emergency rooms, or health care provider%'s office, within first 8 weeks post-discharge
| count of sick visits | Caffeine | Placebo |
|---|---|---|
| Number of All-cause Sick Visits, Urgent Care, Emergency Rooms, or Health Care Provider%'s Office, Within First 8 Weeks Post-discharge | 0 (0 to 0) | 0 (0 to 0) |
Number of sick visits related to apneic or apparent life-threatening events within first 4 weeks post-discharge MEASTYPE=SEC
| count of apnea visits | Caffeine | Placebo |
|---|---|---|
| Number of Sick Visits Related to Apneic or Apparent Life-threatening Events Within First 4 Weeks Post-discharge | 0 (0 to 0) | 0 (0 to 0) |
Number of sick visits related to apneic or apparent life-threatening events within second 4 weeks post-discharge
| count of apnea visits | Caffeine | Placebo |
|---|---|---|
| Number of Sick Visits Related to Apneic or Apparent Life-threatening Events Within Second 4 Weeks Post-discharge | 0 (0 to 0) | 0 (0 to 0) |
Number of sick visits related to apneic or apparent life-threatening events within first 8 weeks post-discharge
| count of apnea visits | Caffeine | Placebo |
|---|---|---|
| Number of Sick Visits Related to Apneic or Apparent Life-threatening Events Within First 8 Weeks Post-discharge | 0 (0 to 0) | 0 (0 to 0) |
Collected over Randomization through 8-weeks post discharge, up to 48 weeks Post-Menstrual Age.. Non-serious events are listed at a 0.00% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Caffeine | 1/416 (0.2%) | 12/416 (2.9%) | 10/416 (2.4%) |
| Placebo | 0/411 (0%) | 22/411 (5.4%) | 24/411 (5.8%) |
| Event | Caffeine | Placebo |
|---|---|---|
| Apnea neonatalRespiratory, thoracic and mediastinal disorders | 2/416 | 9/411 |
| VomitingGastrointestinal disorders | 0/416 | 4/411 |
| Necrotising enterocolitis neonatalGastrointestinal disorders | 0/416 | 2/411 |
| BronchiolitisInfections and infestations | 1/416 | 2/411 |
| Rhinovirus infectionInfections and infestations | 1/416 | 2/411 |
| Sepsis neonatalInfections and infestations | 1/416 | 2/411 |
| Respiratory syncytial virus infectionInfections and infestations | 2/416 | 1/411 |
| Neonatal tachycardiaCardiac disorders | 0/416 | 1/411 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/416 | 1/411 |
| Ileal stenosisGastrointestinal disorders | 0/416 | 1/411 |
| Event | Caffeine | Placebo |
|---|---|---|
| Hypertension neonatalVascular disorders | 9/416 | 10/411 |
| Apnea neonatalRespiratory, thoracic and mediastinal disorders | 1/416 | 9/411 |
| Necrotising enterocolitis neonatalGastrointestinal disorders | 0/416 | 2/411 |
| Sepsis neonatalInfections and infestations | 0/416 | 2/411 |
| HaematocheziaGastrointestinal disorders | 0/416 | 1/411 |
| Arrhythmia neonatalCardiac disorders | 1/416 | 0/411 |
The study recruited infants based on eligibility and parental/guardian consent. Baseline characteristics of the mother were collected (with consent) for use in statistical analysis.
| Age, Continuous(years) | Caffeine | Placebo | Total |
|---|---|---|---|
| Mean | 30 ± 5.8 | 29.9 ± 5.8 | 29.9 ± 5.8 |
| Sex/Gender, Customized(Participants) | Caffeine | Placebo | Total |
|---|---|---|---|
| Female | 213 | 207 | 420 |
| Male | 203 | 204 | 407 |
| Race/Ethnicity, Customized(Participants) | Caffeine | Placebo | Total |
|---|---|---|---|
| American Indian or Alaskan Native | 7 | 12 | 19 |
| Asian | 12 | 9 | 21 |
| Black | 110 | 110 | 220 |
| More Than One Race | 3 | 2 | 5 |
| Native Hawaiian or Other Pacific Islander | 4 | 4 | 8 |
| Unknown | 2 | 2 | 4 |
| Unknown or Not Reported | 13 | 11 | 24 |
| White | 265 | 261 | 526 |
| Race/Ethnicity, Customized(Participants) | Caffeine | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 63 | 54 | 117 |
| Not Hispanic or Latino | 338 | 345 | 683 |
| Unknown | 2 | 2 | 4 |
| Unknown or Not Reported | 13 | 10 | 23 |
| Marital status(Participants) | Caffeine | Placebo | Total |
|---|---|---|---|
| Married | 213 | 233 | 446 |
| Single | 200 | 175 | 375 |
| Unknown | 3 | 3 | 6 |
| Mothers education, Customized(Participants) | Caffeine | Placebo | Total |
|---|---|---|---|
| 8th grade or less | 9 | 5 | 14 |
| 9th to 12th grade | 33 | 22 | 55 |
| College degree | 68 | 75 | 143 |
| Graduate degree | 38 | 38 | 76 |
| High School degree | 86 | 102 | 188 |
| Partial college/Associate degree | 93 | 90 | 183 |
| Trade or technical school | 10 | 10 | 20 |
| Unknown | 79 | 69 | 148 |
| Mothers insurance, Customized(Participants) | Caffeine | Placebo | Total |
|---|---|---|---|
| Private | 207 | 213 | 420 |
| Public | 203 | 190 | 393 |
| Self-pay/uninsured | 6 | 7 | 13 |
| Unknown | 0 | 1 | 1 |
| Gravidity(years) | Caffeine | Placebo | Total |
|---|---|---|---|
| Median | 2.5 (1 to 4) | 2 (1 to 4) | 2 (1 to 4) |
11 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Per NIH Data Sharing Plan
Ran from Feb 2019 to primary completion in Jan 2023, 46 months.
Results were first posted in Jun 2024, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Caffeine citrate
NICHD Neonatal Research Network